The Predictive Role of CYP3A4 and MDA in Duration-Dependent Oxidative and Metabolic Hepatic Alterations among Chronic Methamphetamine Users

Abstract

Background: Methamphetamine (METH) is a powerful psych stimulant that causes hepatotoxic and neurotoxic effects through metabolic disruption and oxidative stress. Despite growing evidence of liver impairment brought on by methamphetamine, it is still unclear how exposure duration affects oxidative markers and cytochrome P450 (CYP3A4) activity.

Objectives: The objective of this study was to determine how long-term methamphetamine usage is associated with liver abnormalities, to find out if long-term exposure makes oxidative and metabolic problems worse, and to determine whether these biochemical changes happen before or at the same time as changes in LFTs, which would explain how methamphetamine causes progressive liver damage. 

Methods: A case-control study was performed on 116 male individuals aged 18 to 40 years, including 80 METH users divided into two groups according to the duration of use (G1 3-5 years; n =44 and G2 6-8 years; n = 36) and 36 control participants. Serum CYP3A4, MDA, LFTs, albumin, total protein, and globulin levels were measured.

Results: Age and body mass index did not significantly differ across groups. (p > 0.05). CYP3A4 levels were markedly reduced in both METH user groups compared with controls (p<0.001) where MDA levels were significantly elevated (p<0.001), showing a duration-dependent increase. ALT, AST, and ALP were significantly higher in long-term users (p<0.05). While total protein and albumin increased significantly in both groups (p<0.001).

Conclusions: Prolonged METH exposure induced progressive oxidative and metabolic hepatic alteration that preceded clinically apparent hepatotoxicity. CYP3A4 inhibition and MDA elevation serve as sensitive early biomarkers for detecting subclinical hepatic impairment in chronic METH users, underscoring their potential value as early diagnostic.